Latest news with #Myriad
Yahoo
09-06-2025
- Yahoo
Demolition of old Myriad Convention Center underway Monday
OKLAHOMA CITY (KFOR) – Demolition for the north wall of the old Myriad Convention Center and Pedestrian Skybridge begins Monday, June 9. After more than five decades of being a centerpiece for events in Oklahoma City, the time for the old Cox Convention Center is up. LOCAL NEWS: Snake season: What to do if a venomous snake bites you? 'It's meant a lot, but it's lived its life,' Maps Program Manager for the city of Oklahoma City David Todd said. 'And it's in a prime spot where we're going to put a new arena.' Demolition for the 145-foot long pedestrian skybridge and the buildings north wall started Monday and will last through the week. The total project is expected to be finished by September. 'People forget there's a garage under there,' Todd said. 'There's going to be a 14 foot hole right there in that area that'll have to eventually be filled. So, the demolition is complicated in some aspects.' Street closures and disruptions to the OKC Street Car will last through the end of the week. Sheridan Avenue from Robinson Avenue to the Century Center Parking Garage will be down to one westbound lane. Meanwhile, Sheridan Avenue will be completely closed east of the garage all the way to E.K. Gaylord Boulevard. 'There's access that will be provided to Mahogany and some of the other businesses in the garage there. You just have to follow the signs,' Todd said. To make way for progress, the OKC Streetcar will have to be shut down temporarily. Until it's back up and running, shuttle buses will help people get around downtown. Per the City of Oklahoma City, 'EMBARK will operate a dedicated bus shuttle to shuttle riders along a modified Downtown Loop from 6 a.m. – midnight. Buses will run every 25 minutes. Streetcar fare is required via ticket vending machines or the Token Transit mobile app. Riders can board the shuttle at any streetcar platform along the route, with the exception of the Century Center stop on Sheridan. Bus head signs will read 'OKC Streetcar Service Downtown Loop.' Real-time tracking will not be available, so please allow extra travel time. If you need assistance navigating the streetcar shuttle, you can call EMBARK Customer Service at 405-235-RIDE (7433). The call center is open Monday-Friday from 7:30 a.m. – 6:30 p.m.' LOCAL NEWS: PHOTOS: Community showing support for Oklahoma City Thunder Plenty to keep in mind as crews work for the foreseeable future and mark the end of an era in Oklahoma City. The demolition is considered 'mechanical', meaning no explosives are going to be used. The wrecking company over the project told the city that they plan to recycle all steel and concrete from the demolition site. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
09-06-2025
- Business
- Yahoo
First day of Cox Convention Center demolition marks major change to downtown OKC
Downtown dwellers and visitors will have to sharpen their navigation skills as the building formerly known as the Myriad and the Cox Convention Center goes through major demolition this week. The north wall and the pedestrian skybridge are currently scheduled for removal during the week of June 9-13, leading to lane closures on Sheridan Avenue. The demolition process is expected to last through the rest of the year. There haven't been any delays because the work has been all interior so far, said Kristen Torkelson, arena communications liaison. The work is being done as the city prepares to present renderings for the new NBA arena that will be built in the footprint of the old convention center. The renderings are expected to be shown during Mayor David Holt's State of the City address on June 16, Torkelson said. More: Exclusive: OKCThunder Films pays homage to OKC icon in new film premiering at deadCenter Sheridan Avenue, from Robinson Avenue to E.K. Gaylord Boulevard, is closed. The Century Center parking garage can be accessed by the southbound lane on N. Broadway Avenue, and one westbound lane on Sheridan Avenue is open. People staying at the Wyndham Grand Hotel can access it by making a U-turn at the end of N. Broadway Avenue. The OKC Streetcar is temporarily shut down, but Embark will operate a dedicated shuttle bus along a modified downtown loop. Riders should allow for extra travel time as real-time tracking won't be available. The city said in a news release most of the sidewalk around the center remains open, with some portions closed, but accessible ramps are open at all four corners. More: Cox Convention Center demolition to start by April; memories to be preserved As the process keeps going, Midwest Wrecking, the demolition company contracted by the city, is working to remove debris from inside the building and tearing down steel from the walls to recycle it, Torkelson said. After the north wall and the sky bridge is down, work will start on dismantling the east and west walls and then work toward the center of the building. This article originally appeared on Oklahoman: OKC Cox Convention Center demolition begins with sky bridge
GMA Network
04-06-2025
- Entertainment
- GMA Network
Alden Richards makes directorial debut in 'Out of Order'
Alden Richards is set to make his directorial debut in the upcoming film "Out of Order." Aside from being the director, Alden also stars in the film alongside Nonie Buencamino and Heaven Peralejo. The film, a collaboration between Viva Films and Alden's company Myriad, will premiere in the competition section of the third Da Nang Asian Film Festival in Vietnam from June 29 to July 5. In May, Alden flew to South Korea and met Tom Cruise during the "Mission Impossible: The Final Reckoning premiere." Alden is set to host the upcoming Kapuso dance competition "Stars on the Floor," which will premiere on GMA Network in June. After starring in the Kapuso series "Pulang Araw" and the blockbuster movie "Hello, Love, Again" last year, Alden returned to "All-Out Sundays" in February. —Hermes Joy Tunac/MGP, GMA Integrated News
The Australian
30-05-2025
- Business
- The Australian
Long Shortz: Aroa Biosurgery
Tylah Tully chats with Aroa Biosurgery (ASX:ARX) founder and CEO Brian Ward on the company's FY25 results, posting its first profit since listing on the ASX in 2020. The company had a strong year, reporting total revenue of NZ$84.7 million, 23% growth on FY24. In particular, Myriad™ notched just over NZ$32 million in product revenue, 38% growth on the previous financial year. Watch the video to hear Ward's insights. This video was developed in collaboration with Aroa Biosurgery, a Stockhead client at the time of publishing. The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.
News.com.au
29-05-2025
- Business
- News.com.au
Health Check: Aroa's ‘hero' product propels the wound management house back into black
Aroa shares surge 13% after the company's full-year results exceeded guidance New wound management IPO does the rounds for $35 million Inoviq shares vault up to 58% on early cancer light therapy results Kiwi-based wounds management house Aroa Biosurgery (ASX:ARX) has exceeded its recent revenue and earnings guidance, after a robust second half on the back of its 'hero' Myriad product range. Aroa's revenue came in at NZ$84.7 million for the year to March 2025, 23% higher and slightly above the NZ$81-84 million range the company guided to in late April. Normalised earnings before interest tax depreciation and amortisation (ebitda) were NZ$4.2 million, compared with the previous NZ$3.1 million loss. Once again, the number was a tad above the guided range of NZ$2-4 million. Aroa has also guided to current-year revenue of NZ$92-100 million, 10-20% higher year on year, with ebitda of NZ$5-8 million. CEO Brian Ward stresses the company's 'star product' Myriad has been delivering the goods, with sales up 35%. Myriad is used for complex wounds including trauma and lower limb salvage. Sold via Aroa's partner TELA Bio, sales of its hernia and breast reconstruction tool Ovitex rose 22% Sales of the Endoform wound dressing were flat, as expected. Expanding indications Ward said the company would focus on expanding indications for its products, which are biological materials sourced from ovine intestines. This push is being supported by several clinical studies, such as a lower limb salvage study trial that resulted in quick healing with no complications. 'That's quite different to what we have seen with other technologies,' he says. However, Aroa has 'paused' the rollout of its Symphony product, for hard-to-heal wounds such as diabetic ulcers. This is because the company has won inpatient reimbursement in the US, but not coverage for physicians. The company plans a supportive trial to win full reimbursement. 'The rules are changing and only products with randomised, controlled trials will be reimbursed,' Ward says. 'This will take many rivals out of the market.' Aroa has product approvals across 50 countries, but almost all its revenue derives from the US. CFO James Agnew said the US tariff impact on the company was likely to be around NZ$1.5 million, or around 1% of revenue. Because of transfer pricing arrangements between TELA Bio and Aroa's own US entity, that's far less than the blanket 10% rate Uncle Sam levies on NZ goods. New wound play does the IPO rounds Still on wound management, Tetraherix is defying the barren IPO biotech landscape with a $35 million raising to advance its novel tools for applications including tissue healing, bone regeneration and surgical spacing. Invented by chemical engineer and University of Sydney researcher Dr Ali Fathi, the platform-based tech is the world's first 'biostealth fluid matrix'. Supplied in ready-to-use syringes, the polymer is injected into the relevant anatomy and sets to a 'chewing-gum' consistency that can be easily moulded to suit the application. Eventually, the material breaks down into water and carbon dioxide. Pending expected US Food and Drug Approval, the company hopes to bring its first products to market in the first half of 2026. These are for dental applications and bone regeneration and orthopaedic uses. The company also has tools in the pipeline for scar prevention during surgery and a prostate surgery 'spacer' to protect surrounding tissue (such as the rectum) during radiation therapy. Doing the rounds Joint lead managers Morgans and Barrenjoey are undertaking the institution round which closes next Tuesday, with a limited retail offering open until June 17. The company is expected to list in late June. The shares are offered at $2.88 a pop, amounting to a $155 million market cap and a $115 million enterprise value (allowing for cash on hand). The founder of 'cloud' accounting software giant Xero, Rod Drury is a notable investor. Invion lights up on skin cancer trial The developer of photodynamic therapies (PTDs) for cancers, Invion (ASX:IVX) has passed the initial safety test for its phase I/II non-melanoma skin cancer trial, being carried out in Queensland (of course). A safety review committee found no 'adverse events' among the first treated patients, who were administered Invion's candidate INV-043 as an ointment. What's more, 'early indications show an observable reduction in the lesion size after a single treatment cycle'. Clinician feedback shows patients did not experience any pain during the treatment, 'which compares favourably to currently approved PDT treatments.' By combining oxygen and light, PTDs are known to kill malignant cells and shut down tumors. Known about for more than a century, the science is supported by more than 500 trials. That said, it's been an overlooked area of oncology and Invion is the only listed exemplar. Invion now is proceeding to the second stage of the adaptive trial, which involves dose optimalisation. Meanwhile, the safety data will influence the company's upcoming phase I/II trial for ano-genital cancer, in alliance with the Peter MacCallum Cancer Centre. Known for wild movements, Invion shares soared up to 58% this morning. Inoviq share freeze highlights disclosure dilemmas A quirky aspect of clinical results is they are not validated until they are presented in a prestigious peer-reviewed publication, or a conference of luminaries. Typically, a company will post top-line results earlier and this can lead to investor confusion about what's new and what's merely additional info for the boffins. On Monday, the ASX suspended share trading in cancer drug developer Inoviq (ASX:IIQ) and queried why the company's shares soared 25%, from 37 cents on Wednesday May 21, to last Friday's high of 46.5 cents. Inoviq yesterday pointed to an abstract poster presentation for an upcoming American Society of Clinical Oncology (ASCO) conference published online. This outlined 'the background, methods, results and conclusions underpinning the high-level results' of an independent patient validation study of the company's ovarian cancer test. The results of the blood test were 'outstanding', with more than 94% accuracy. Hold the front page! Okay, let it go: the guts of the results were outlined on December 3 last year – and referred to in subsequent ASX disclosures. Inoviq says: 'some shareholders may have missed or misunderstood the significance of and may believe the abstract contains new or better information, which is materially price sensitive.' The company believes that was not the case and did not 'announce' the abstract to the ASX. Fair enough! After all, there's nothing more frustrating than companies hyping up presentations that contain no genuine news. In old tabloid terms it's known as a Bamix job: a beat up. But like all good tabloid yarns, there's a twist: Inoviq will present further trial information that is price sensitive, to the ASCO powwow in Chicago on Sunday. This prezzo is under embargo until that day and Inoviq plans to announce the 'tightly held' information first thing on Monday. In the meantime, it's best the shares remain untradeable.
